Loading
A phase 1/2 trial of Pembrolizumab in melanoma and colorectal cancer, run by GeneMedicine Co., Ltd., now recruiting.
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06265025 by GeneMedicine Co., Ltd., with 125 participants planned, started 2024-02-20 and due to reach its primary completion in 2025-05-30. Interventions recorded: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C). Conditions listed: Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/